All In Biotech

Drug Trial Radar · NCT05475106

Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms

Pilot Study of Personalized Neoantigen Peptide Vaccines and Leukine for the Treatment of Neoplasms

Last checked: Nov 20, 2026Latest source record: Mar 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

May 12, 2022

Primary completion

Nov 25, 2025

Study completion Jun 20, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The present study is a pilot clinical trial using personalized neoantigen peptide vaccines with the addition of Leukine (Sargramostim), in patients with different types of cancer.

Conditions

  • Neoplasms

Interventions

  • Neoantigen PeptidesBiological

    Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 4 weeks, and every month for 5 months after that.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in WBC countTime frame: Baseline, 2, 6, 12 months
  2. Change from Baseline in RBC countTime frame: Baseline, 2, 6, 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Instituto de Medicina Regenerativa

    Tijuana, Estado de Baja California, Mexico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.